ArticleMolecular therapy. Nucleic acids2024

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas.

Pedro Justicia-Lirio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.